Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

被引:130
|
作者
del Alcazar, Carlos Rodrigo Gil [1 ]
Hardebeck, Molly Catherine [1 ]
Mukherjee, Bipasha [1 ]
Tomimatsu, Nozomi [1 ]
Gao, Xiaohuan [1 ]
Yan, Jingsheng [2 ]
Xie, Xian-Jin [2 ]
Bachoo, Robert [3 ]
Li, Li [3 ,4 ]
Habib, Amyn A. [3 ,4 ]
Burma, Sandeep [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA
[4] VA North Texas Hlth Care Syst, Dallas, TX USA
基金
美国国家航空航天局;
关键词
PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; DEPENDENT PROTEIN-KINASE; RAPAMYCIN INHIBITOR; PRECLINICAL EVALUATION; ADJUVANT TEMOZOLOMIDE; DAMAGE RESPONSE; CANCER-CELLS; IN-VIVO; ATM; RADIOTHERAPY;
D O I
10.1158/1078-0432.CCR-13-1607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Inhibitors of the DNA damage response (DDR) have great potential for radiosensitization of numerous cancers, including glioblastomas, which are extremely radio- and chemoresistant brain tumors, Currently, there are no DNA double-strand break (DSB) repair inhibitors that have been successful in treating glioblastoma. Our laboratory previously demonstrated that the dual phosphoinositide 3-kinase/mTOR inhibitor NVP-BEZ235 can potently inhibit the two central DDR kinases, DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and ataxia-telangiectasia mutated (ATM), in vitro, Here, we tested whether NVP-BEZ235 could also inhibit ATM and DNA-PKcs in tumors in viva and assessed its potential as a radio- and chemosensitizer in preclinical mouse glioblastoma models. Experimental Design: The radiosensitizing effect of NVP-BEZ235 was tested by following tumor growth in subcutaneous and ortho topic glioblastoma models, Tumors were generated using the radioresistant U87-vIII glioma cell line and GBM9 neurospheres in nude mice. These tumors were then treated with ionizing radiation and/or NVP-BEZ235 and analyzed for DNA-PKcs and ATM activation, DSB repair inhibition, and attenuation of growth. Results: NVP-BEZ235 potently inhibited both DNA-PKcs and ATM kinases and attenuated the repair of ionizing radiation-induced DNA damage in tumors. This resulted in striking tumor radiosensitization, which extended the survival of brain tumor-bearing mice. Notably, tumors displayed a higher DSB-load when compared with normal brain tissue. NVP-BEZ235 also sensitized a subset of subcutaneous tumors to temozolomide, a drug routinely used concurrently with ionizing radiation for the treatment of glioblastoma. Conclusions: These results demonstrate that it may be possible to significantly improve glioblastoma therapy by combining ionizing radiation with potent and bioavailable DNA repair inhibitors such as NVP-BEZ235. (C) 2013 AACR.
引用
收藏
页码:1235 / 1248
页数:14
相关论文
共 50 条
  • [21] Discovery of NVP-BEZ235 - A dual PI3K/mTOR inhibited for targeted cancer treatment
    Garcia-Echeverria, Carlos
    JOURNAL OF BIOMOLECULAR SCREENING, 2008, 13 (07) : 697 - 698
  • [22] The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKcs-mediated DNA damage responses
    Mukherjee, Bipasha
    Tomimatsu, Nozomi
    Amancherla, Kaushik
    Camacho, Cristel
    Burma, Sandeep
    CANCER RESEARCH, 2012, 72
  • [23] The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses
    Mukherjee, Bipasha
    Tomimatsu, Nozomi
    Amancherla, Kaushik
    Camacho, Cristel V.
    Pichamoorthy, Nandini
    Burma, Sandeep
    NEOPLASIA, 2012, 14 (01): : 34 - U53
  • [24] Radiation Sensitization of Head and Neck Tumor Cells using the dual PI3K/mTOR Inhibitor NVP-BEZ235
    Balzer, V.
    Subtil, F.
    Dikomey, E.
    Engenhart-Cabillic, R.
    Schoetz, U.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S233 - S233
  • [25] NVP-BEZ235, a dual PI3K/mTOR inhibitor, may be effective for ovarian clear cell carcinoma cells
    Oishi, Tetsuro
    Itamochi, Hiroaki
    Nonaka, Michiko
    Sato, Seiya
    Naniwa, Jun
    Uegaki, Kazunori
    Sato, Shinya
    Shimada, Muneaki
    Terakawa, Naoki
    Kigawa, Junzo
    Harada, Tasuku
    CANCER RESEARCH, 2011, 71
  • [26] The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells
    Li, Chuntuan
    Xin, Pengliang
    Xiao, Huifang
    Zheng, Yan
    Huang, Yuanling
    Zhu, Xiongpeng
    CANCER CELL INTERNATIONAL, 2015, 15
  • [27] The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells
    Chuntuan Li
    Pengliang Xin
    Huifang Xiao
    Yan Zheng
    Yuanling Huang
    Xiongpeng Zhu
    Cancer Cell International, 15
  • [28] Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
    Xie, Chencheng
    Freeman, Matthew J.
    Lu, Huarui
    Wang, Xiaohong
    Forster, Colleen L.
    Sarver, Aaron L.
    Hallstrom, Timothy C.
    ONCOTARGET, 2017, 8 (24) : 38084 - 38098
  • [29] The dual Inhibitor BEZ235 of the PI3K/mTor-Signaling Pathway enhances the Radiosensitivity of HNSCC-Cells by Inhibiting Double-strand Break Repair
    Arenz, A.
    Balzer, V
    Dreffke, K.
    Wittig, A.
    Rieckmann, T.
    Koecher, S.
    Dikomey, E.
    U, Schoetz
    Engenhart-Cabillic, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S11 - S12
  • [30] NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Serra, Violeta
    Markman, Ben
    Scaltriti, Maurizio
    Eichhorn, Pieter J. A.
    Valero, Vanesa
    Guzman, Marta
    Luisa Botero, Maria
    Llonch, Elisabeth
    Atzori, Francesco
    Di Cosimo, Serena
    Maira, Michel
    Garcia-Echeverria, Carlos
    Lluis Parra, Josep
    Arribas, Joaquin
    Baselga, Jose
    CANCER RESEARCH, 2008, 68 (19) : 8022 - 8030